Cargando…

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine

The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected 1 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurhade, Chaitanya, Zou, Jing, Xia, Hongjie, Cai, Hui, Yang, Qi, Cutler, Mark, Cooper, David, Muik, Alexander, Jansen, Kathrin U., Xie, Xuping, Swanson, Kena A., Shi, Pei‑Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225806/
https://www.ncbi.nlm.nih.gov/pubmed/35739094
http://dx.doi.org/10.1038/s41467-022-30681-1
_version_ 1784733702490685440
author Kurhade, Chaitanya
Zou, Jing
Xia, Hongjie
Cai, Hui
Yang, Qi
Cutler, Mark
Cooper, David
Muik, Alexander
Jansen, Kathrin U.
Xie, Xuping
Swanson, Kena A.
Shi, Pei‑Yong
author_facet Kurhade, Chaitanya
Zou, Jing
Xia, Hongjie
Cai, Hui
Yang, Qi
Cutler, Mark
Cooper, David
Muik, Alexander
Jansen, Kathrin U.
Xie, Xuping
Swanson, Kena A.
Shi, Pei‑Yong
author_sort Kurhade, Chaitanya
collection PubMed
description The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected 1 month after dose 3) against the three Omicron sublineages. To facilitate the neutralization testing, we have engineered the complete BA.1, BA.2, or BA.3 spike into an mNeonGreen USA-WA1/2020 SRAS-CoV-2. All BNT162b2-vaccinated sera neutralize USA-WA1/2020, BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s with titers of >20; the neutralization geometric mean titers (GMTs) against the four viruses are 1211, 336, 300, and 190, respectively. Thus, the BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s are 3.6-, 4.0-, and 6.4-fold less efficiently neutralized than the USA-WA1/2020, respectively. Our data have implications in vaccine strategy and understanding the biology of Omicron sublineages.
format Online
Article
Text
id pubmed-9225806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-92258062022-06-24 Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine Kurhade, Chaitanya Zou, Jing Xia, Hongjie Cai, Hui Yang, Qi Cutler, Mark Cooper, David Muik, Alexander Jansen, Kathrin U. Xie, Xuping Swanson, Kena A. Shi, Pei‑Yong Nat Commun Article The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected 1 month after dose 3) against the three Omicron sublineages. To facilitate the neutralization testing, we have engineered the complete BA.1, BA.2, or BA.3 spike into an mNeonGreen USA-WA1/2020 SRAS-CoV-2. All BNT162b2-vaccinated sera neutralize USA-WA1/2020, BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s with titers of >20; the neutralization geometric mean titers (GMTs) against the four viruses are 1211, 336, 300, and 190, respectively. Thus, the BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s are 3.6-, 4.0-, and 6.4-fold less efficiently neutralized than the USA-WA1/2020, respectively. Our data have implications in vaccine strategy and understanding the biology of Omicron sublineages. Nature Publishing Group UK 2022-06-23 /pmc/articles/PMC9225806/ /pubmed/35739094 http://dx.doi.org/10.1038/s41467-022-30681-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kurhade, Chaitanya
Zou, Jing
Xia, Hongjie
Cai, Hui
Yang, Qi
Cutler, Mark
Cooper, David
Muik, Alexander
Jansen, Kathrin U.
Xie, Xuping
Swanson, Kena A.
Shi, Pei‑Yong
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
title Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
title_full Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
title_fullStr Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
title_full_unstemmed Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
title_short Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
title_sort neutralization of omicron ba.1, ba.2, and ba.3 sars-cov-2 by 3 doses of bnt162b2 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225806/
https://www.ncbi.nlm.nih.gov/pubmed/35739094
http://dx.doi.org/10.1038/s41467-022-30681-1
work_keys_str_mv AT kurhadechaitanya neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT zoujing neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT xiahongjie neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT caihui neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT yangqi neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT cutlermark neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT cooperdavid neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT muikalexander neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT jansenkathrinu neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT xiexuping neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT swansonkenaa neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine
AT shipeiyong neutralizationofomicronba1ba2andba3sarscov2by3dosesofbnt162b2vaccine